\n(Valores em milhares de d\u00f3lares americanos e n\u00e3o auditados)<\/p>\n<\/td>\n<\/tr>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
Tr\u00eas meses terminados em<\/b><\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
2026<\/b><\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
2025<\/b><\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
\n\u00a0<\/p>\n<\/td>\n
Varia\u00e7\u00e3o em %<\/b><\/p>\n<\/td>\n<\/tr>\n \nReceita l\u00edquida do produto<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.487.329<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.108.530<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n34<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nOutras receitas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n26.109<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n8.749<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n198<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nReceita total<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,513.438<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.117.279<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n35<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional de acordo com os GAAP<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n249.902<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n11.102<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2.151<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional ajustado*<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n414.394<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n139.357<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n197<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro l\u00edquido de acordo com os GAAP<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n227.357<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.270<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17.802<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nLucro l\u00edquido ajustado*<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n375.042<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n136.137<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n175<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o b\u00e1sico (EPS) de acordo com os GAAP por ADS<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n2,05<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n20.400<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o b\u00e1sico ajustado por ADS*<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n3,38<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,27<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n166<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o dilu\u00eddo de acordo com os GAAP por ADS<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,96<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19.500<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o dilu\u00eddo ajustado por ADS*<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n3,24<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,22<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n166<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa livre*<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n160.547<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n(12.325<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.403<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n * Para obter uma explica\u00e7\u00e3o sobre o uso de medidas financeiras n\u00e3o GAAP, consulte a se\u00e7\u00e3o \u201cNota sobre o uso de medidas financeiras n\u00e3o GAAP\u201d mais adiante neste comunicado à imprensa; para uma reconcilia\u00e7\u00e3o de cada medida financeira n\u00e3o GAAP com as medidas GAAP mais compar\u00e1veis, consulte a tabela no final deste comunicado à imprensa.<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Resultados financeiros do primeiro trimestre de 2026<\/span><\/b><\/p>\n \nA receita com produtos<\/b> totalizou US$ 1,5 bilh\u00e3o, representando um crescimento de 34% em rela\u00e7\u00e3o ao mesmo per\u00edodo do ano anterior.<\/p>\n \nA margem bruta<\/b>, como porcentagem das vendas totais de produtos no primeiro trimestre de 2026, foi de 89%, ante 85% no mesmo per\u00edodo do ano anterior, segundo os princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP). Esse aumento se deve a uma composi\u00e7\u00e3o de vendas proporcionalmente maior do BRUKINSA global em rela\u00e7\u00e3o aos outros produtos de nosso portf\u00f3lio. A margem bruta tamb\u00e9m se beneficiou de melhorias na produtividade, resultando em custos mais baixos tanto para o BRUKINSA quanto para o TEVIMBRA.<\/p>\n Despesas operacionais<\/b><\/p>\n \nA tabela a seguir resume as despesas operacionais do primeiro trimestre de 2026:<\/p>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n GAAP<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n N\u00e3o GAAP<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n (n\u00e3o auditado, em milhares, exceto porcentagens)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 1\u00ba trim. de 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 1\u00ba trim. de 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Varia\u00e7\u00e3o em %<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 1\u00ba trim. de 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 1\u00ba trim. de 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Varia\u00e7\u00e3o em %<\/b><\/p>\n<\/td>\n<\/tr>\n \nPesquisa e desenvolvimento<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n541.224<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n481.887<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n465.904<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n421.195<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nDespesas com vendas, gerais e administrativas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n555.097<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n459.288<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n21<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n471.993<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n395.511<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n \nDespesas operacionais totais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.096.321<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n941.175<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n937.897<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n816.706<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n15<\/p>\n<\/td>\n \n%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n As despesas com pesquisa e desenvolvimento (P&D)<\/b> aumentaram no primeiro trimestre de 2026 em rela\u00e7\u00e3o ao mesmo per\u00edodo do ano anterior, tanto segundo os princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP) quanto em termos ajustados, devido ao avan\u00e7o de programas pr\u00e9-cl\u00ednicos para a fase cl\u00ednica e de programas cl\u00ednicos em fase inicial para a fase avan\u00e7ada.<\/p>\n As despesas com vendas, gerais e administrativas (SG&A) tamb\u00e9m<\/b> aumentaram no primeiro trimestre de 2026, tanto com base nos princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP) quanto em termos ajustados, devido ao investimento cont\u00ednuo para apoiar o crescimento comercial. As despesas SG&A como porcentagem das vendas de produtos foram de 37% no primeiro trimestre de 2026, ante 41% no mesmo per\u00edodo do ano anterior.<\/p>\n Lucro l\u00edquido e lucro por a\u00e7\u00e3o b\u00e1sico\/dilu\u00eddo<\/b><\/p>\n \nO lucro l\u00edquido GAAP para o primeiro trimestre de 2026 foi de US$ 227 milh\u00f5es, um aumento de US$ 226 milh\u00f5es em rela\u00e7\u00e3o ao mesmo per\u00edodo do ano anterior, principalmente devido ao crescimento da receita e à melhoria da alavancagem operacional.<\/p>\n \nNo primeiro trimestre de 2026, o lucro b\u00e1sico e dilu\u00eddo por a\u00e7\u00e3o foi de US$ 0,16 e US$ 0,15, respectivamente, e de US$ 2,05 e US$ 1,96 por American Depositary Share (ADS), em compara\u00e7\u00e3o com o lucro b\u00e1sico e dilu\u00eddo por a\u00e7\u00e3o de US$ 0,00 e US$ 0,01 por ADS, respectivamente, no mesmo per\u00edodo do ano anterior.<\/p>\n \nO fluxo de caixa livre<\/b> no primeiro trimestre de 2026 foi de US$ 161 milh\u00f5es, valor 173% maior que o registrado no mesmo per\u00edodo do ano anterior.<\/p>\n \nPara mais detalhes sobre as demonstra\u00e7\u00f5es financeiras do primeiro trimestre de 2026 da BeOne, consulte o relat\u00f3rio trimestral da empresa no formul\u00e1rio 10-Q para o primeiro trimestre de 2026, arquivado na Comiss\u00e3o de Valores Mobili\u00e1rios dos Estados Unidos (U.S. Securities and Exchange Commission \u2013 SEC).<\/p>\n Previs\u00f5es atualizadas para o ano fiscal de 2026<\/span><\/b><\/p>\n \nAs previs\u00f5es financeiras da BeOne est\u00e3o resumidas a seguir:<\/p>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Previs\u00f5es para o exerc\u00edcio fiscal de 2026<\/b><\/p>\n<\/td>\n Previs\u00f5es atuais para o exerc\u00edcio fiscal de 20261<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n Receita total<\/b><\/p>\n<\/td>\n \n6,2 a 6,4 bilh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n \n6,3 a 6,5 bilh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n<\/tr>\n Margem bruta segundo os GAAP (%)<\/b><\/p>\n<\/td>\n \nIntervalo superior a 80%<\/p>\n<\/td>\n \nIntervalo superior a 80%<\/p>\n<\/td>\n<\/tr>\n Despesas operacionais de acordo com os GAAP2<\/sup><\/b><\/p>\n \n(P&D e despesas administrativas e de vendas combinadas)<\/p>\n<\/td>\n \n4,7 a 4,9 bilh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n \n4,7 a 4,9 bilh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n<\/tr>\n Lucro operacional de acordo com os GAAP2<\/sup><\/b><\/p>\n<\/td>\n \n700 a 800 milh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n \n750 a 850 milh\u00f5es de d\u00f3lares<\/p>\n<\/td>\n<\/tr>\n Lucro operacional n\u00e3o GAAP2,3<\/sup><\/b><\/p>\n<\/td>\n \nUS$ 1,4 a US$ 1,5 bilh\u00e3o<\/p>\n<\/td>\n \nUS$ 1,45 bilh\u00e3o – US$ 1,55 bilh\u00e3o<\/p>\n<\/td>\n<\/tr>\n 1<\/sup> Com base nas taxas de c\u00e2mbio de 1\u00ba de maio de 2026. \nA previs\u00e3o de receita total da BeOne para todo o ano de 2026 est\u00e1 entre US$ 6,3 e US$ 6,5 bilh\u00f5es e inclui a expectativa de um forte crescimento da receita, impulsionado pela posi\u00e7\u00e3o de lideran\u00e7a do BRUKINSA nos EUA e pela expans\u00e3o global cont\u00ednua, tanto na Europa quanto em outros mercados importantes ao redor do mundo. Espera-se que a margem bruta fique na faixa alta dos 80%, considerando o impacto do mix de produtos e as melhorias de produtividade ao longo de todo o ano. A previs\u00e3o de despesas operacionais combinadas, com base nos princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP), inclui expectativas de investimento para apoiar o crescimento nas \u00e1reas comercial e de pesquisa, a um ritmo que continue a proporcionar uma alavancagem operacional significativa.<\/p>\n \nA empresa fornece as seguintes orienta\u00e7\u00f5es adicionais sobre itens que afetam o lucro l\u00edquido e o lucro por ADS:<\/p>\n Destaques dos neg\u00f3cios do primeiro trimestre de 2026<\/span><\/b><\/p>\n Principais produtos comercializados<\/b><\/p>\n BRUKINSA<\/i>(zanubrutinibe)<\/i><\/p>\n Sonrotoclax (inibidor de BCL2)<\/i><\/p>\n TEVIMBRA<\/i>(tislelizumabe)<\/i><\/p>\n ZIIHERA (zanidatamabe)<\/i><\/p>\n Programas selecionados em fase cl\u00ednica<\/b><\/p>\n Hematologia<\/i><\/p>\n C\u00e2nceres de mama e ginecol\u00f3gicos:<\/i><\/p>\n C\u00e2nceres gastrointestinais<\/i><\/p>\n C\u00e2ncer de pulm\u00e3o<\/i><\/p>\n Inflama\u00e7\u00e3o e imunologia<\/i><\/p>\n Marcos previstos de P&D<\/b><\/p>\n Programas<\/b><\/p>\n<\/td>\n Prazo<\/b><\/p>\n<\/td>\n<\/tr>\n BRUKINSA<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n \n1\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n \n\u2022<\/p>\n<\/td>\n \n1\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n \n\u2022<\/p>\n<\/td>\n \n2\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n TEVIMBRA<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n \n1\u00ba sem. de 2027<\/p>\n<\/td>\n<\/tr>\n Hematologia<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nMedida regulat\u00f3ria da FDA relativa ao pedido de registro de novo medicamento para o tratamento em monoterapia de pacientes adultos com MCL recidivante ou refrat\u00e1rio.<\/p>\n<\/td>\n \n1\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nIn\u00edcio do estudo de Fase 3 para o tratamento de pacientes adultos com mieloma m\u00faltiplo resistente ao tratamento ou recorrente com transloca\u00e7\u00e3o t(11;14).<\/p>\n<\/td>\n \n2\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n \n\u2022<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nPoss\u00edvel submiss\u00e3o para aprova\u00e7\u00e3o acelerada na Fase 2 (caso os dados o sustentem) para o tratamento de pacientes adultos com LLC recidivante\/refrat\u00e1ria.<\/p>\n<\/td>\n \n2\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n Mama\/Ginecol\u00f3gico<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n C\u00e2nceres<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nIn\u00edcio do estudo de fase 3 para o tratamento de pacientes adultos com c\u00e2ncer de mama metast\u00e1tico HR-positivo e HER2-negativo em primeira linha.<\/p>\n<\/td>\n \n1\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n C\u00e2ncer de pulm\u00e3o<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nIn\u00edcio do primeiro estudo em seres humanos.<\/p>\n<\/td>\n \n1\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n Gastrointestinal<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n C\u00e2nceres<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nIn\u00edcio do estudo pivotal de Fase 3.<\/p>\n<\/td>\n \n2\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n Inflama\u00e7\u00e3o e<\/b><\/p>\n<\/td>\n \n\u2022<\/p>\n<\/td>\n Imunologia<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u25e6<\/p>\n<\/td>\n \nIn\u00edcio do estudo de Fase 2 para o tratamento de pacientes adultos com urtic\u00e1ria cr\u00f4nica espont\u00e2nea.<\/p>\n<\/td>\n \n2\u00ba sem. de 2026<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Atualiza\u00e7\u00f5es corporativas:<\/b><\/p>\n Webcast dos resultados financeiros da BeOne<\/b><\/p>\n \nA teleconfer\u00eancia sobre os resultados financeiros da empresa para o primeiro trimestre de 2026 ser\u00e1 transmitida via webcast \u00e0s 8h (hor\u00e1rio da costa leste dos EUA) na quarta-feira, dia 6 de maio de 2026, e poder\u00e1 ser acessada na se\u00e7\u00e3o \u201cInvestidores\u201d do site da BeOne, no site www.beonemedicines.com<\/a>. Informa\u00e7\u00f5es suplementares na forma de apresenta\u00e7\u00e3o de slides, transcri\u00e7\u00e3o das declara\u00e7\u00f5es preparadas e uma grava\u00e7\u00e3o do webcast tamb\u00e9m estar\u00e3o dispon\u00edveis.<\/p>\n Sobre a BeOne<\/b><\/p>\n \nA BeOne Medicines \u00e9 uma empresa global de oncologia que descobre e desenvolve tratamentos inovadores para pacientes com c\u00e2ncer em todo o mundo. Com um portf\u00f3lio que abrange hematologia e tumores s\u00f3lidos, a BeOne acelera o desenvolvimento de sua diversificada linha de novas terapias por meio de suas capacidades internas e colabora\u00e7\u00f5es. A empresa conta com uma equipe global em expans\u00e3o, presente em seis continentes, impulsionada pela excel\u00eancia cient\u00edfica e pela agilidade excepcional para alcan\u00e7ar mais pacientes do que nunca.<\/p>\n \nPara saber mais sobre a BeOne, acesse www.beonemedicines.com<\/a> e nos siga no LinkedIn<\/a>, X<\/a>, Facebook<\/a> e Instagram<\/a> Declara\u00e7\u00f5es Prospectivas<\/p>\n \nEste comunicado à imprensa cont\u00e9m declara\u00e7\u00f5es prospectivas, conforme definido na Lei de Reforma de Lit\u00edgios de Valores Mobili\u00e1rios Privados de 1995 (Private Securities Litigation Reform Act of 1995) e em outras leis federais de valores mobili\u00e1rios, incluindo declara\u00e7\u00f5es sobre: o crescimento cont\u00ednuo da BeOne como l\u00edder global em oncologia; a combina\u00e7\u00e3o de dura\u00e7\u00e3o fixa de sonrotoclax e BRUKINSA como um potencial novo padr\u00e3o de tratamento de primeira linha para leucemia linfoc\u00edtica cr\u00f4nica (LLC); o surgimento do BGB-16673 como uma potencial terapia inovadora para LLC recidivante\/refrat\u00e1ria; a receita futura da BeOne, a porcentagem de margem bruta, as despesas operacionais, o lucro operacional, outras receitas ou despesas, o imposto de renda e os American Depositary Shares (ADS) dilu\u00eddos em circula\u00e7\u00e3o; as expectativas da BeOne em rela\u00e7\u00e3o à expans\u00e3o global cont\u00ednua e ao investimento para apoiar o crescimento; os pr\u00f3ximos marcos de Pesquisa & Desenvolvimento (P&D) a serem alcan\u00e7ados pela BeOne; o cronograma de desenvolvimentos cl\u00ednicos e regulat\u00f3rios e a divulga\u00e7\u00e3o de dados; e os planos, compromissos, aspira\u00e7\u00f5es e metas da BeOne. O t\u00edtulo \u201cSobre a BeOne\u201d. Os resultados reais podem diferir materialmente daqueles indicados nas declara\u00e7\u00f5es prospectivas em decorr\u00eancia de diversos fatores importantes, incluindo a capacidade da BeOne de demonstrar a efic\u00e1cia e a seguran\u00e7a de seus candidatos a medicamentos, os resultados cl\u00ednicos de seus candidatos a medicamentos (que podem n\u00e3o sustentar o desenvolvimento adicional ou a aprova\u00e7\u00e3o de comercializa\u00e7\u00e3o), as a\u00e7\u00f5es de ag\u00eancias reguladoras (que podem afetar o in\u00edcio, o cronograma e o progresso dos ensaios cl\u00ednicos e a aprova\u00e7\u00e3o de comercializa\u00e7\u00e3o), a capacidade da BeOne de obter sucesso comercial com seus medicamentos comercializados e candidatos a medicamentos (caso sejam aprovados), a capacidade da BeOne de obter e manter a prote\u00e7\u00e3o da propriedade intelectual de seus medicamentos e tecnologia, a depend\u00eancia da BeOne de terceiros para conduzir o desenvolvimento, a fabrica\u00e7\u00e3o, a comercializa\u00e7\u00e3o e outros servi\u00e7os relacionados a medicamentos e a experi\u00eancia limitada da BeOne na obten\u00e7\u00e3o de aprova\u00e7\u00f5es regulat\u00f3rias. A BeOne est\u00e1 sujeita a diversos riscos, como os relacionados à pesquisa e ao desenvolvimento de medicamentos, à sua capacidade de obter financiamento adicional para opera\u00e7\u00f5es e concluir o desenvolvimento de seus candidatos a medicamentos, bem como alcan\u00e7ar e manter a lucratividade. Esses riscos s\u00e3o discutidos mais detalhadamente na se\u00e7\u00e3o intitulada \u201cFatores de Risco\u201d do relat\u00f3rio peri\u00f3dico mais recente da empresa, arquivado junto à Comiss\u00e3o de Valores Mobili\u00e1rios dos EUA ( U.S. Securities and Exchange Commission \u2013 SEC), como tamb\u00e9m nas discuss\u00f5es sobre riscos potenciais, incertezas e outros fatores importantes presentes nos relat\u00f3rios subsequentes da BeOne junto à SEC. Todas as informa\u00e7\u00f5es contidas neste comunicado à imprensa s\u00e3o v\u00e1lidas na data de sua publica\u00e7\u00e3o, e a BeOne n\u00e3o se compromete a atualiz\u00e1-las, a menos que seja exigido por lei. As proje\u00e7\u00f5es financeiras da BeOne baseiam-se em estimativas e premissas sujeitas a incertezas significativas.<\/p>\n Demonstra\u00e7\u00f5es Consolidadas Condensadas do Resultado Operacional (GAAP dos EUA)<\/b><\/p>\n \n(Valores em milhares de d\u00f3lares americanos, exceto no que se refere a a\u00e7\u00f5es, American Depositary Shares (ADSs) e dados por a\u00e7\u00e3o e por ADS)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Tr\u00eas meses encerrados em<\/b><\/p>\n 31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (n\u00e3o auditado)<\/b><\/p>\n<\/td>\n \nReceitas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReceita l\u00edquida de produtos<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.487.329<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.108.530<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOutras receitas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n26.109<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n8.749<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReceita total<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.513.438<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.117.279<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCusto das vendas – produtos<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n167.215<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n165.002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro bruto<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.346.223<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n952.277<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas operacionais:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nPesquisa e desenvolvimento<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n541.224<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n481.887<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas com vendas, gerais e administrativas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n555.097<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n459.288<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas operacionais totais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.096.321<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n941.175<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n249.902<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11.102<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReceitas de juros<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n27.664<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12.850<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas com juros<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(32.887<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(7.002<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nOutras receitas, l\u00edquidas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n14.536<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.950<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro antes dos impostos sobre o rendimento<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n259.215<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n20.900<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesa com imposto de renda<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n31.858<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19.630<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro l\u00edquido<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n227.357<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.270<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nB\u00e1sico<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,16<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDilu\u00eddo<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,15<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nM\u00e9dia ponderada de a\u00e7\u00f5es em circula\u00e7\u00e3o \u2014 b\u00e1sica<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.442.451,870<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.390.052,966<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nM\u00e9dia ponderada de a\u00e7\u00f5es em circula\u00e7\u00e3o \u2014 dilu\u00edda<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.505.027,338<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.445.253,219<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por A\u00e7\u00e3o Deposit\u00e1ria Americana (\u201cADS\u201d)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nB\u00e1sico<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n2,05<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDilu\u00eddo<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n1,96<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nM\u00e9dia ponderada de ADSs em circula\u00e7\u00e3o \u2014 b\u00e1sica<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n110.957.836<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n106.927.151<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nM\u00e9dia ponderada de ADSs em circula\u00e7\u00e3o \u2014 dilu\u00edda<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n115.771.334<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n111.173.325<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Dados selecionados do balan\u00e7o patrimonial consolidado condensado (GAAP dos EUA)<\/b><\/p>\n \n(Valores em milhares de d\u00f3lares americanos)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n A partir de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n 31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 31 de dezembro de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (n\u00e3o auditado)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n (auditado)<\/b><\/p>\n<\/td>\n<\/tr>\n Ativos:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCaixa, equivalentes de caixa e caixa restrito<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.853.425<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.609.647<\/p>\n<\/td>\n<\/tr>\n \nContas a receber, l\u00edquidas<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n938.019<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n865.080<\/p>\n<\/td>\n<\/tr>\n \nEstoque<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n681.590<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n608.227<\/p>\n<\/td>\n<\/tr>\n \nAtivos imobilizados, l\u00edquidos<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.640.918<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.641.678<\/p>\n<\/td>\n<\/tr>\n \nAtivos totais<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n8.553.619<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n8.188.573<\/p>\n<\/td>\n<\/tr>\n Passivo e patrim\u00f4nio l\u00edquido:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nContas a pagar<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n423.546<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n479.035<\/p>\n<\/td>\n<\/tr>\n \nDespesas a pagar e outras contas a pagar<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.079.283<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.109.120<\/p>\n<\/td>\n<\/tr>\n \nResponsabilidade pela reparti\u00e7\u00e3o dos custos de P&D<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n35.700<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n64.345<\/p>\n<\/td>\n<\/tr>\n \nVenda de direitos futuros sobre royalties<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n904.399<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n906.956<\/p>\n<\/td>\n<\/tr>\n \nD\u00edvida<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.078.655<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.019.206<\/p>\n<\/td>\n<\/tr>\n \nTotal do passivo<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.793.177<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.827.379<\/p>\n<\/td>\n<\/tr>\n \nPatrim\u00f4nio l\u00edquido total<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.760.442<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.361.194<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Demonstra\u00e7\u00f5es de fluxo de caixa consolidadas condensadas (GAAP dos EUA)<\/b><\/p>\n \n(Valores em milhares de d\u00f3lares americanos)<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Tr\u00eas meses encerrados em<\/b><\/p>\n 31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n (n\u00e3o auditado)<\/b><\/p>\n<\/td>\n<\/tr>\n \nCaixa, equivalentes de caixa e caixa restrito no in\u00edcio do per\u00edodo<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.609.647<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n2.638.747<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa l\u00edquido proveniente das atividades operacionais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n201.336<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n44.082<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa l\u00edquido utilizado nas atividades de investimento<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(45.510<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(121.941<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa l\u00edquido proveniente de (utilizado em) atividades de financiamento<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n68.632<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(33.777<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nEfeito l\u00edquido das varia\u00e7\u00f5es nas taxas de c\u00e2mbio<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19.320<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.480<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAumento (redu\u00e7\u00e3o) l\u00edquido de caixa, equivalentes de caixa e caixa restrito<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n243.778<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(108.156<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nCaixa, equivalentes de caixa e caixa restrito no final do per\u00edodo<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n4.853.425<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n2.530.591<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Nota sobre o uso de medidas financeiras n\u00e3o GAAP<\/b><\/p>\n \nA BeOne apresenta certas medidas financeiras n\u00e3o GAAP, incluindo Despesas Operacionais Ajustadas, Preju\u00edzo Operacional Ajustado, Lucro L\u00edquido Ajustado, Lucro por A\u00e7\u00e3o Ajustado, Fluxo de Caixa Livre e certas outras rubricas da demonstra\u00e7\u00e3o de resultados n\u00e3o GAAP, cada uma das quais inclui ajustes nos valores GAAP. Essas medidas financeiras n\u00e3o GAAP t\u00eam como objetivo fornecer informa\u00e7\u00f5es adicionais sobre o desempenho operacional da BeOne. Os ajustes nos valores GAAP da BeOne excluem, conforme aplic\u00e1vel, itens n\u00e3o monet\u00e1rios, tais como remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es, deprecia\u00e7\u00e3o e amortiza\u00e7\u00e3o. Certos outros itens especiais ou eventos substanciais tamb\u00e9m podem ser inclu\u00eddos nos ajustes n\u00e3o GAAP periodicamente, quando sua magnitude for significativa nos per\u00edodos em que ocorreram. Os ajustes n\u00e3o GAAP s\u00e3o tributados na medida em que haja despesa tribut\u00e1ria corrente de acordo com os GAAP dos EUA. A Empresa registra atualmente uma provis\u00e3o de desvaloriza\u00e7\u00e3o sobre seus ativos fiscais diferidos l\u00edquidos, de modo que n\u00e3o h\u00e1 impacto l\u00edquido registrado para efeitos de impostos diferidos. A BeOne mant\u00e9m uma pol\u00edtica n\u00e3o GAAP estabelecida que orienta a determina\u00e7\u00e3o de quais custos ser\u00e3o exclu\u00eddos nas medidas financeiras n\u00e3o GAAP e os protocolos, controles e aprova\u00e7\u00f5es relacionados ao uso de tais medidas. A BeOne acredita que essas medidas financeiras n\u00e3o GAAP, quando consideradas em conjunto com os valores GAAP, podem melhorar a compreens\u00e3o geral do desempenho operacional da BeOne. As medidas financeiras n\u00e3o GAAP s\u00e3o inclu\u00eddas para proporcionar aos investidores uma compreens\u00e3o mais completa dos resultados e das tend\u00eancias financeiras hist\u00f3ricas e esperadas da BeOne, al\u00e9m de facilitar compara\u00e7\u00f5es entre per\u00edodos e em rela\u00e7\u00e3o \u00e0s informa\u00e7\u00f5es projetadas. Al\u00e9m disso, essas medidas est\u00e3o entre os indicadores utilizados pela administra\u00e7\u00e3o da BeOne para planejamento, previs\u00e3o e mensura\u00e7\u00e3o do desempenho da empresa. Essas medidas devem ser consideradas em conjunto com as medidas financeiras calculadas de acordo com os princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP), e n\u00e3o como substitutas ou superiores a elas. As medidas financeiras n\u00e3o GAAP utilizadas pela BeOne podem ser calculadas de maneira diferente das utilizadas por outras empresas e, portanto, podem n\u00e3o ser compar\u00e1veis a elas.<\/p>\n RECONCILIA\u00c7\u00c3O DE INDICADORES GAAP SELECIONADOS COM INDICADORES N\u00c3O GAAP<\/b><\/p>\n (Valores em milhares de d\u00f3lares americanos, exceto os dados por a\u00e7\u00e3o e por ADS)<\/b><\/p>\n (n\u00e3o auditado)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Tr\u00eas meses encerrados em<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n 31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre os princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP) e o custo ajustado de vendas \u2013 produtos:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCusto das vendas segundo os GAAP – produtos<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n167.215<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n165.002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4.326<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2.613<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Amortiza\u00e7\u00e3o de ativos intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.742<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.173<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCusto ajustado das vendas – produtos<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n161.147<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n161.216<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre os princ\u00edpios cont\u00e1beis geralmente aceitos (GAAP) e os gastos ajustados com pesquisa e desenvolvimento:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nPesquisa e desenvolvimento de acordo com os GAAP<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n541.224<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n481.887<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Custo com remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n53.856<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n41.767<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n21.464<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n18.925<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nPesquisa e desenvolvimento ajustados<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n465.904<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n421.195<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre os valores cont\u00e1beis (GAAP) e as despesas ajustadas com vendas, gerais e administrativas:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas com vendas, gerais e administrativas (GAAP)<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n555.097<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n459.288<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Custo com remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n69.492<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n53.684<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n13.595<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n10.076<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Amortiza\u00e7\u00e3o de ativos intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas ajustadas com vendas, gerais e administrativas<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n471.993<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n395.511<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o das despesas operacionais de acordo com os GAAP com as despesas operacionais ajustadas<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas operacionais de acordo com os GAAP<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.096.321<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n941.175<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Custo com remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n123.348<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.451<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n35.059<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n29.001<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: Amortiza\u00e7\u00e3o de ativos intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDespesas operacionais ajustadas<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n937.897<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n816.706<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre o resultado operacional de acordo com os GAAP e o resultado operacional ajustado:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional de acordo com os GAAP<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n249.902<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n11.102<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: custo de compensa\u00e7\u00e3o baseado em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n123.348<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.451<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n39.385<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n31.614<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.759<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.190<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional ajustado<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n414.394<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n139.357<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre o resultado l\u00edquido de acordo com os GAAP e o resultado l\u00edquido ajustado:<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro l\u00edquido de acordo com os GAAP<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n227.357<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1.270<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: despesas de compensa\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n123.348<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.451<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n39.385<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n31.614<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.759<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.190<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: perda por redu\u00e7\u00e3o ao valor recuper\u00e1vel de investimentos em participa\u00e7\u00f5es societ\u00e1rias<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12.376<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: itens fiscais pontuais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.535<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5.473<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: efeito do imposto de renda dos ajustes n\u00e3o GAAP1<\/sup><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(20.342<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(11.237<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nLucro l\u00edquido ajustado<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n375.042<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n136.137<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o do GAAP para o EPS ajustado \u2013 b\u00e1sico<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o (GAAP) \u2013 b\u00e1sico<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,16<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: despesas de compensa\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,09<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,07<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,03<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,02<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: perda por redu\u00e7\u00e3o ao valor recuper\u00e1vel de investimentos em participa\u00e7\u00f5es societ\u00e1rias<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: itens fiscais pontuais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: efeito do imposto de renda dos ajustes n\u00e3o GAAP1<\/sup><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,01<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,01<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o ajustado \u2013 b\u00e1sico<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,26<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,10<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o entre o GAAP e o lucro por a\u00e7\u00e3o ajustado – dilu\u00eddo<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o segundo os GAAP – dilu\u00eddo<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,15<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: despesas de compensa\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,08<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,07<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,03<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,02<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: perda por redu\u00e7\u00e3o ao valor recuper\u00e1vel de investimentos em participa\u00e7\u00f5es societ\u00e1rias<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: itens fiscais pontuais<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: efeito do imposto de renda dos ajustes n\u00e3o GAAP1<\/sup><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,01<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,01<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nLucro por a\u00e7\u00e3o ajustado – dilu\u00eddo<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,25<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,09<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o dos resultados de acordo com os GAAP com o lucro ajustado por ADS \u2013 b\u00e1sico<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por ADS segundo os GAAP – b\u00e1sico<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n2,05<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: despesas de compensa\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,11<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,89<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,35<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,30<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,02<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: perda por redu\u00e7\u00e3o ao valor recuper\u00e1vel de investimentos em participa\u00e7\u00f5es societ\u00e1rias<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,12<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: itens fiscais discretos<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,03<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,05<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: efeito do imposto de renda dos ajustes n\u00e3o GAAP1<\/sup><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,18<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,11<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nLucro ajustado por ADS \u2013 b\u00e1sico<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n3,38<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,27<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o dos resultados de acordo com os GAAP com o lucro por ADS ajustado \u2013 dilu\u00eddo<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro por ADS segundo os GAAP \u2013 dilu\u00eddo<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,96<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: despesas com remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,07<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,86<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: deprecia\u00e7\u00e3o<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,34<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,28<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: amortiza\u00e7\u00e3o de ativos intang\u00edveis<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,02<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: perdas por redu\u00e7\u00e3o do valor de investimentos em participa\u00e7\u00f5es societ\u00e1rias<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,00<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,11<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: itens fiscais discretos<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,03<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0,05<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMais: efeito do imposto de renda dos ajustes n\u00e3o-GAAP1<\/sup><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,18<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0,10<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nLucro ajustado por ADS \u2013 dilu\u00eddo<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n3,24<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n1,22<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Tr\u00eas meses encerrados em<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 31 de mar\u00e7o de<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Fluxo de caixa livre (n\u00e3o GAAP):<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa l\u00edquido proveniente das atividades operacionais (GAAP)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n201.336<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n44.082<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nMenos: aquisi\u00e7\u00f5es de ativos imobilizados<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(40.789<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(56.407<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nFluxo de caixa livre (n\u00e3o GAAP)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n160.547<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \nUS$<\/p>\n<\/td>\n \n(12.325<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reconcilia\u00e7\u00e3o das orienta\u00e7\u00f5es sobre o lucro operacional de acordo com os GAAP com os resultados n\u00e3o GAAP<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Previs\u00e3o do lucro operacional para o ano inteiro de 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (n\u00e3o auditado)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional de acordo com os GAAP<\/p>\n<\/td>\n \n750.000<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n850.000<\/p>\n<\/td>\n<\/tr>\n \nMais: ajustes para chegar ao resultado n\u00e3o GAAP1<\/sup><\/p>\n<\/td>\n \n700.000<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n700.000<\/p>\n<\/td>\n<\/tr>\n \nLucro operacional n\u00e3o GAAP<\/p>\n<\/td>\n \n1.450.000<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.550.000<\/p>\n<\/td>\n<\/tr>\n \nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n Ver a vers\u00e3o original em businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260506520852\/pt\/<\/a><\/span><\/p>\n Contato:<\/b><\/p>\n \nContato para investidores\n<\/p>\n Liza Heapes\n<\/p>\n +1 857-302-5663\n<\/p>\n ir@beonemed.com Contato para a m\u00eddia\n<\/p>\n Kyle Blankenship\n<\/p>\n +1 667-351-5176\n<\/p>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n \n \n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/td>\n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n \n
\n
2<\/sup> N\u00e3o leva em considera\u00e7\u00e3o nenhuma poss\u00edvel nova atividade de desenvolvimento de neg\u00f3cios relevante nem itens incomuns ou n\u00e3o recorrentes.
\n
3<\/sup> O lucro operacional n\u00e3o GAAP \u00e9 um indicador financeiro que exclui, em rela\u00e7\u00e3o ao indicador GAAP correspondente, os custos relacionados à remunera\u00e7\u00e3o baseada em a\u00e7\u00f5es e as despesas com deprecia\u00e7\u00e3o e amortiza\u00e7\u00e3o. A proje\u00e7\u00e3o pressup\u00f5e que as despesas n\u00e3o GAAP acompanhem o crescimento geral das despesas.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n \n Marcos importantes<\/b><\/td>\n \n \n \n \n An\u00e1lise provis\u00f3ria dos dados do estudo MANGROVE de fase 3, que compara o tratamento com rituximabe em monoterapia versus bendamustina mais rituximabe no tratamento de pacientes adultos com LCM em primeira linha.<\/td>\n \n \n <\/td>\n \n Aprova\u00e7\u00e3o regulat\u00f3ria no Jap\u00e3o para o tratamento de pacientes adultos com c\u00e2ncer g\u00e1strico de primeira linha.<\/td>\n \n \n <\/td>\n \n A FDA dos EUA aprovou a decis\u00e3o regulat\u00f3ria para o tratamento de pacientes adultos com GEA HER2-positivo em primeira linha, em combina\u00e7\u00e3o com ZIIHERA.<\/td>\n \n \n \n \n A aprova\u00e7\u00e3o regulat\u00f3ria na China permite o tratamento de pacientes adultos com GEA HER2-positivo em primeira linha, em combina\u00e7\u00e3o com ZIIHERA.<\/td>\n \n \n \n \n Sonrotoclax (inibidor de BCL2):<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n \n \n \n \n \n <\/td>\n \n \n \n \n \n <\/td>\n \n BGB-16673 (BTK CDAC):<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n \n \n \n \n \n \n \n BGB-43395 (inibidor de CDK4):<\/td>\n <\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n BON-110 (anticorpo triespec\u00edfico PD-1xVEGF-AxCTLA-4):<\/td>\n \n \n <\/td>\n \n \n \n \n \n \n \n BGB-B2033 (anticorpo biespec\u00edfico GPC3x41BB):<\/td>\n \n \n \n \n \n \n \n \n \n \n BGB-16673 (BTK CDAC):<\/td>\n <\/td>\n<\/tr>\n \n \n \n \n \n \n \n
\n
\n \n \n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/td>\n <\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n <\/td>\n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n 1. O efeito fiscal dos ajustes n\u00e3o GAAP baseia-se na al\u00edquota de imposto prevista na legisla\u00e7\u00e3o da jurisdi\u00e7\u00e3o fiscal em quest\u00e3o. Observe que a Empresa atualmente registra uma provis\u00e3o para desvaloriza\u00e7\u00e3o sobre seus ativos fiscais diferidos l\u00edquidos; portanto, n\u00e3o h\u00e1 impacto l\u00edquido registrado para os efeitos fiscais diferidos.<\/td>\n<\/tr>\n<\/table>\n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n \u00a0<\/td>\n<\/tr>\n \n 1. Os ajustes n\u00e3o GAAP baseiam-se nas melhores informa\u00e7\u00f5es dispon\u00edveis no momento, relacionadas a itens n\u00e3o monet\u00e1rios semelhantes aos relatados em nossos resultados n\u00e3o GAAP efetivos.<\/td>\n<\/tr>\n<\/table>\n <\/span><\/p>\n
\n<\/a><\/p>\n<\/p>\n